title: Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.
abstract: Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which is characterized by autoimmune like inflammatory responses and reduced levels of regulatory T cells (Tregs). Recently, the use of low-dose IL-2 has been reported to selectively increase Tregs and therefore facilitate immune regulation and promote clinical improvements in cGVHD patients. In this report, we describe the case of a cGVHD patient who was treated with daily low-dose IL-2 therapy. Our observations demonstrate that low-dose IL-2 could induce significant expansion of Tregs in vivo leading to improved Treg/Th17 ratios. The patient showed moderate clinical benefits suggesting that multiple factors may be involved in the immunological responses. Therefore, while the therapeutic potential of low-dose IL-2 is promising, strategic approaches may be needed to induce a clinically significant and sustained Treg effect.
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
authors.forename: Nayoun
authors.initials: N
authors.lastname: Kim
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea; The Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.
authors.forename: Young-Woo
authors.initials: YW
authors.lastname: Jeon
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
authors.forename: Young-Sun
authors.initials: YS
authors.lastname: Nam
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
authors.forename: Jung-Yeon
authors.initials: JY
authors.lastname: Lim
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
authors.forename: Keon-Il
authors.initials: KI
authors.lastname: Im
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
authors.forename: Eun-Sol
authors.initials: ES
authors.lastname: Lee
authors.affiliation: The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea; The Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea. Electronic address: chosg@catholic.ac.kr.
authors.forename: Seok-Goo
authors.initials: SG
authors.lastname: Cho
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D006086:Graft vs Host Disease / Q000276:immunology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007167:Immunotherapy; D055104:Infusions, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D058504:Th17 Cells
chemical_list: D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin
keywords: Allogeneic hematopoietic stem cell transplantation; Chronic graft-versus-host disease; Immunotherapy; Interleukin-2; Regulatory T cell